OFFICIAL CONFERENCE COVERAGE

Data From the XVIII International AIDS Conference (AIDS 2010)

CCO's comprehensive coverage of AIDS 2010 in Vienna, Austria, includes Capsule Summaries of the most clinically relevant data presented at the meeting, audio highlights, an original CCO highlights slideset, and a CME-certified Expert Analysis to help you understand the implications of these new data for clinical practice.

To browse available coverage, click here.

Managing First-line Therapy in 2 Cases of HIV/Hepatitis-Coinfected Patients
Jürgen Rockstroh, MD, and Mark S. Sulkowski, MD, join Program Director Eric S. Daar, MD, to discuss the evaluation and treatment of 2 chronically infected hepatitis patients who require treatment for their HIV infection.

Managing First-line Therapy in 2 Cases Involving Comorbidity and Treatment Intolerance
Grace McComsey, MD, and William G. Powderly, MD, offer management strategies for 2 difficult-to-manage cases. Program Director Paul E. Sax, MD, challenges them to defend their choices. With whom do you agree? Join the discussion to find out.

Managing First-line Therapy in 2 Cases Involving Female Patients

Integrating HIV Therapeutic Advances Into Clinical Practice—Volume 3, Edition 3
In this edition of Stay Tuned:

• Pablo Tebas, MD, discusses implications of recent data suggesting that certain antiretroviral agents are associated with loss in bone mineral density and renal disease.
• Scott L. Letendre, MD, discusses possible causes and implications of neurocognitive disease in HIV-infected patients.
• Cecile Tremblay, MD, FRPC, reviews data that can help guide clinicians on whether and when to perform integrase and CCR5 inhibitor resistance tests, along with which tests are available. 
• Susan Buchbinder, MD, discusses recent results on the potential ability of microbicides and antiretrovirals to prevent HIV acquisition. 
• Donna Futterman, MD, reviews the importance of routine HIV testing and linkage to care in all healthcare settings, along with strategies to streamline this process.

Audio, video, Capsule Summaries, and slideset downloads are also provided for additional reference. Click here to start.

Update on Antiretroviral Therapy
Joseph J. Eron, Jr., MD, provides a comprehensive update on recently reported data on antiretroviral therapy, encompassing studies in treatment-naive and treatment-experienced patients and investigational agents.

Immunosenescence of Aging and HIV
Alan L. Landay, PhD, and Seema Desai, PhD, provide an overview of cellular aging and immune activation and discuss data that indicate that this process is accelerated in patients infected with HIV-1.

HIV and Cardiovascular Disease
Virginia A. Triant, MD, MPH, reviews factors relevant to risk of cardiovascular disease in HIV-infected patients, including HIV infection itself, antiretroviral therapy, lifestyle, and other comorbidities.

HIV/HCV: Staying Alive in 2010
Mark S. Sulkowski, MD, reviews the prognosis of treated and untreated HIV/HCV-coinfected patients as well as factors predictive of treatment success and the role of liver transplantation in this population.

Management of Sexually Transmitted Diseases in the HIV Care Setting
Jeanne Marrazzo, MD, MPH, discusses recent data on diagnosis and treatment of sexually transmitted diseases in the HIV care setting, particularly syphilis, gonorrhea, genital herpes, and human papillomavirus.

Applying Best Practices for HIV-Infected Patients With Initial Regimen Failure
Joseph J. Eron, Jr., MD, provides a case-based review of the latest clinical data on the optimal strategies for treating patients with initial regimen failure including recommendations from a panel of CCO’s expert faculty members.

Choosing a Second-Line Regimen for a Patient Failing an Initial NNRTI-Based Regimen With K103N Alone
2 NRTIs + boosted PI? 2 NRTIs + raltegravir? What about maraviroc? Joseph J. Eron, Jr., MD, reviews the evidence that supports the choice of the second regimen after failure of an NNRTI-based initial regimen. Challenge yourself to choose the correct course!

Choosing a Second-Line Regimen for a Middle-Aged Man With Cardiovascular Disease Failing an Initial Raltegravir-Based Regimen
Eric S. Daar, MD, discusses factors to be considered in planning subsequent therapy for this patient. See if you can choose the best regimen for second-line therapy for this patient.

Choosing a Second-Line Regimen for a Patient Failing a Boosted PI Regimen With Wild-Type Virus
This clinical scenario may seem straightforward but it actually requires careful scrutiny of the patient’s adherence. Kimberly Y. Smith, MD, MPH, discusses the management of this patient and the evaluation that must be undertaken.

Choosing a Second-Line Regimen for a Schizophrenic Patient Failing an Initial Boosted PI Regimen With Multiple Resistance Mutations
Daniel R. Kuritzkes, MD, reviews this very complicated case and discusses data from the DUET and TRIO trials that might inform concerning the choice of agents for the second regimen.

Integrating HIV Therapeutic Advances Into Clinical Practice—Volume 3, Edition 2
In this edition of Stay Tuned:

• Keith Henry, MD, reviews the most recent updates to the DHHS guidelines regarding when to start antiretroviral therapy
• Paul E. Sax, MD, discusses a case that illustrates some of the changes made to the preferred regimens in the updated 2009 DHHS guidelines
• Joseph J. Eron, Jr., MD, discusses final results from ACTG 5202 presented at the 2010 retroviruses conference
• W. David Hardy, MD, discusses the clinical implications of the FDA’s recent expanded indication for maraviroc to include treatment-naive patients
• Kenneth Mayer, MD, reviews the results of the recent Thai vaccine trial and provides insight into how they may hold promise for future vaccine research

Audio, video, Capsule Summaries, and slideset downloads are also provided for additional reference. Click here to start.

From Podium to Practice: Clinical Impact of New Data From San Francisco
Joel E. Gallant, MD, MPH; José Gatell, MD; and Kimberly Y. Smith, MD, MPH, review the most noteworthy new data on HIV-1 infection presented at the 2010 Conference on Retroviruses and Opportunistic Infections.

Update on Timing and Choice of Antiretroviral Therapy
Eric S. Daar, MD, summarizes new data presented at the 2010 Conference on Retroviruses and Opportunistic Infections on the optimal timing of antiretroviral therapy initiation and first-line regimen selection.

HIV Highlights From San Francisco
Joel E. Gallant, MD, MPH, provides an overview of the highlights from the San Francisco meeting.

Timing and Choice of First-line Antiretroviral Therapy
Eric S. Daar, MD, and William G. Powderly, MD, review the most clinically relevant data on timing and treatment of first-line antiretroviral therapy from the San Francisco meeting.

Integrating HIV Therapeutic Advances Into Clinical Practice—Volume 3, Edition 1
In this edition of Stay Tuned, Eric S. Daar, MD, discusses data presented at the 2009 Interscience Conference on Antimicrobial Agents and Chemotherapy on new agents for HIV in the development pipeline; Kathleen E. Squires, MD, provides insight into the management of HIV-infected pregnant women; Kimberly Y. Smith, MD, MPH, discusses the lower response rates to antiretroviral therapy among black patients and strategies to address this issue; Douglas Ward, MD, discusses emerging data on drug interactions between antiretrovirals, tobacco, and recreational drugs; and Robert W. Coombs, MD, PhD, FRCPC, discusses newer HIV-1 RNA tests and provides insight into the clinical implications of more precise HIV-1 RNA monitoring. Audio, video, Capsule Summaries, and slideset downloads are also provided for additional reference. Click here to start.

Answering the Questions: Clinical Considerations in the Use of Integrase Inhibitors
William G. Powderly, MD; Paul E. Sax, MD; and Jonathan M. Schapiro, MD, address pressing questions regarding the use of HIV integrase inhibitors in clinical practice.

Faculty Responses to Additional Questions on the Use of Integrase Inhibitors in Clinical Practice
William G. Powderly, MD; Paul E. Sax, MD; and Jonathan M. Schapiro, MD, answer the most compelling questions posed by readers on the use of integrase inhibitors in clinical practice.

From Podium to Practice: HIV Highlights From San Francisco
Judith S. Currier, MD, MSc; Joel E. Gallant, MD, MPH; and Kathleen E. Squires, MD, review the most noteworthy data on HIV testing and treatment presented at the 2009 Interscience Conference on Antimicrobial Agents and Chemotherapy and discuss how these new findings may be applicable in clinical practice.

Class in Session: Defining the Role of the Newest Class of Antiretrovirals
Joseph J. Eron Jr., MD; Richard Haubrich, MD; Daniel R. Kuritzkes, MD; and Paul E. Sax, MD, discuss the science behind the use of integrase inhibitors, clinical studies of integrase inhibitors, and the role of these agents in managing HIV-infected patients.

The Science of Integrase Strand Transfer Inhibitors (INSTIs): New Insights and Clinical Implications
This downloadable slideset reviews the science behind integrase inhibitors, including a discussion of relevant drug-drug interactions.

Studies of Integrase Inhibitors Across the Treatment Spectrum
This downloadable slideset reviews the latest clinical data on integrase inhibitors.

The Current Role of Integrase Inhibitors in Clinical Practice
This downloadable slideset reviews practical strategies for using integrase inhibitors in clinical practice.

Weighing the Options for First-line Antiretroviral Therapy
Edwin DeJesus, MD, FACP, AAHIVS, discusses clinical trial information to help participants weigh the options for choosing first-line antiretroviral therapy.

First-line Antiretroviral Therapy: Finding the Right Fit
David A. Wohl, MD, discusses critical factors involved in choosing an initial antiretroviral regimen for individual patients.

Weighing the Options for First-Line Antiretroviral Therapy
Participate in case management decisions with Joseph J. Eron, Jr., MD, as he reviews the most pertinent clinical issues regarding the initial selection of antiretroviral treatment for patients infected with HIV-1.

Weighing the Options for First-line Antiretroviral Therapy
Joseph J. Eron, Jr., MD, challenges the participants with data that should be considered when choosing an initial antiretroviral regimen for a treatment-naive patient.